Avalo Therapeutics, Inc.
AVTX
$9.88
$0.515.44%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 80.31% | 6.75% | |||
| Gross Profit | -80.31% | -10.59% | |||
| SG&A Expenses | -5.48% | 5.98% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 31.68% | 8.64% | |||
| Operating Income | -31.68% | -10.20% | |||
| Income Before Tax | -57.90% | 62.69% | |||
| Income Tax Expenses | 100.00% | -92.98% | |||
| Earnings from Continuing Operations | -57.92% | 62.79% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -57.92% | 62.79% | |||
| EBIT | -31.68% | -10.20% | |||
| EBITDA | -31.98% | -9.75% | |||
| EPS Basic | -53.33% | 63.61% | |||
| Normalized Basic EPS | -53.31% | 63.70% | |||
| EPS Diluted | -53.54% | 63.61% | |||
| Normalized Diluted EPS | -53.31% | 63.70% | |||
| Average Basic Shares Outstanding | 2.99% | 2.77% | |||
| Average Diluted Shares Outstanding | 2.99% | 2.77% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||